Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Aesku
| Company | Aesku |
|---|---|
| Name of instrument | HELIOS HTC |
| City, State | Des Plaines, IL |
| Phone | 844-544-5044 |
| Website | |
| Type of instrument | immunoassay |
| Operational type/Model type | batch/benchtop |
| List price/First year sold in U.S. | $175, 000/2017 |
| Targeted hospital bed size/Targeted test volume | 200–1, 000/daily: > 25; monthly: > 500; annual: > 5, 000 |
| Company manufactures instrument | yes |
| Other models in this family of analyzers | HELMED, HELIA |
| No. of units in clinical use in U.S./Outside U.S. (countries) | > 60/> 500 (Europe, North and South America, Asia, Africa, more) |
| Dimensions (H × W × D)/Instrument footprint | 22.5 x 25.6 x 29.6 in./5.25 sq. ft. |
| Weight empty/Weight fully loaded | 73 lbs./— |
| No. of different measured assays onboard simultaneously | 4 (4 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | — |
| No. of direct ion-selective electrode channels | — |
| Detection methods | — |
| • Ion-selective electrode | — |
| • Basic metabolic panel | — |
| • Complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | — |
| Methodologies supported | fluorescence, indirect fluorescent antibody |
| Separation methodologies | coated IFA slide |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Approximate No. of tests per reagent set/Reagent type | 180/— |
| Reagents refrigerated onboard/Reagents ready to use | no/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (closed reagent system)/no |
| Separate reagent pack for each specimen/for each test run | no/yes |
| Walkaway capability/Walkaway duration | yes/190 specimens or 240 tests |
| Design of sample-handling system | rack |
| Uses washable cuvettes/Uses disposable cuvettes | no/no |
| Min.–max. sample volume that can be aspirated at one time | — |
| Min. reaction volume/Min. specimen volume/Min. dead volume | —/assay dependent/tube dependent |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes (11–16 x 55–100 mm) |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | no/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | hemolysis, icterus, lipemia, clots not available |
| Dilutes patient samples onboard/Susceptibility to carryover | yes/no carryover |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Analyzer requires dedicated water supply | no |
| Autocalibration/Multipoint calibration supported | no (calibrants are not stored onboard)/— |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | — |
| Automatic programmable start/Automatic programmable shutdown | no/no |
| Supports multiple QC lot numbers per analyte | — |
| Waste management | — |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, UPC, Code 39, Code 128, Matrix 2/5, Code 11, EAN/JAN, more)/yes |
| Lab can control analyzer from remote computer | yes |
| Instrument can diagnose its own malfunctions | — |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | optional add-on (HERA lab management system)/Sunquest, Orchard |
| LIS interface provided/Bidirectional interface capability | no/yes (host query) |
| Modem servicing provided/Service engineer on-site response time | no/— |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: 5 min.; weekly: 20 min. |
| Maintenance records kept onboard for user/vendor | no/no |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes (1 training slot)/— |
| Advanced operator training/Extra charge for follow-up or advanced training | yes/— |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (1 year)/— |
| Distinguishing features (supplied by company) | provides all-in-one IFA ANA, ANCA, and nDNA slide processing and reading on one instrument; FDA cleared to identify seven HEp-2 patterns plus negative results; AI pattern-recognition software and endpoint titer estimation |